TransCode Therapeutics (NASDAQ:RNAZ – Get Free Report)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a report issued on Thursday,Benzinga reports. They currently have a $20.00 price target on the stock.
TransCode Therapeutics Trading Up 4.8 %
TransCode Therapeutics stock opened at $0.78 on Thursday. TransCode Therapeutics has a fifty-two week low of $0.65 and a fifty-two week high of $66.33. The firm has a 50 day moving average price of $5.54 and a 200 day moving average price of $237.59.
About TransCode Therapeutics
Recommended Stories
- Five stocks we like better than TransCode Therapeutics
- What Do S&P 500 Stocks Tell Investors About the Market?
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- Roth IRA Calculator: Calculate Your Potential Returns
- How Super Micro Computer Stock Is Defying the Market Sell-Off
- Investing In Automotive Stocks
- AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
Receive News & Ratings for TransCode Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransCode Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.